Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Noubar Afeyan Biography and Net Worth

Director of Moderna

Noubar Afeyan (born July 25, 1962), is an American entrepreneur, venture capitalist, inventor, technologist, and CEO. In 2000, Afeyan founded Flagship Pioneering to create and fund early-stage start-ups addressing unmet needs in healthcare and sustainability. He is a Senior Lecturer at the MIT Sloan School of Management. He lectures in the United States and internationally on topics ranging from entrepreneurship, innovation, and venture capital to biological engineering, drug discovery, medical technologies, and renewable energy.

Afeyan is of Armenian heritage and was born in Beirut, Lebanon. His family moved to Montreal, Canada in 1976. Afeyan graduated from McGill University with a BS in Chemical Engineering in 1983. He earned his PhD in Biochemical Engineering from the Massachusetts Institute of Technology in 1987.

In 1988, Afeyan founded PerSeptive Biosystems in Cambridge, MA. While CEO of PerSeptive, Afeyan co-founded and funded numerous other biotechnology companies, including ChemGenics Pharmaceuticals, acquired by Millennium Pharmaceuticals in 1997; Exact Sciences (NASDAQ:EXAS), Agenus (NASDAQ:AGEN); and Color Kinetics, acquired by Philips 2007. After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, he became Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics.

In 2000, Afeyan founded Flagship Ventures (renamed Flagship Pioneering in 2016), where he currently serves as Senior Managing Partner and CEO. Flagship Pioneering focuses on creating and investing in first-in-category, high-value life science companies in three principal business sectors: therapeutics, health technologies, and sustainability. The company creates companies through a systemic model of entrepreneurial science. Flagship's team of scientists poses scientific hypotheses, works to finesse them, and conducts proof-of-concept experiments that eventually led to new scientific IP and companies with disruptive potential. Since 2000 this process has led to the launch of around 40 companies. The firm also works with external academic innovations and, in some cases, with early-stage companies looking to partner.

Through his work as an entrepreneur both before and at Flagship Pioneering, Afeyan has founded or helped start numerous companies, including Affinnova, Adnexus (acquired by Bristol Myers Squibb), BG Medicine, BIND Therapeutics, Celexion, Eleven Biotherapeutics, Ensemble Therapeutics, Joule Unlimited, LS9, Midori, Moderna Therapeutics, Permeon Biologics, Pronutria Biosciences (later renamed Axcella Health) and Seres Therapeutics.

In 2007, Afeyan and David Berry (inventor) co-founded Joule Unlimited, which is developing Solar Fuels—drop-in fuels produced directly from the sun. In March 2010 and in March 2011, Joule was named by Technology Review as one of the 50 Most Innovative Companies. Joule was named as one of the 10 most important emerging technologies in 2010. Joule's unique and innovative approach to fuels led to its being named a Technology Pioneer by the World Economic Forum in 2012 and to its receiving the Silver Medal in the 2011 Wall Street Journal Technology Innovation Awards. Joule's technology has been scaled to a demonstration facility, and the company has announced a commercial partnership with Audi. Afeyan cofounded Moderna Therapeutics with Kenneth Chien of Harvard University and the Karolinka Institutet, Robert Langer of the Massachusetts Institute of Technology, and Derrick Rossi of Boston Children’s Hospital. The company launched from Flagship Pioneering’s innovation foundry, VentureLabs, in 2010. Since launch, Moderna has raised venture funding in excess of $1B.

Since 2000, Afeyan has been teaching courses on entrepreneurship, innovation, and leadership at the Massachusetts Institute of Technology’s Sloan School of Management. From 2007 to 2010, he also served on Boston University’s Board of Overseers. Afeyan has authored numerous scientific publications and patents.

Afeyan is Chairman of the Global Agenda Council on Emerging Technologies of the World Economic Forum. He is also co-founder and board member of the National Competitiveness Foundation of Armenia, a private-public partnership to promote economic development in the former Soviet Republic of Armenia. He serves on the board of Ameriabank, a leading bank in Armenia. Afeyan serves on multiple charitable and corporate boards, including those of Codiak Biosciences, Evelo Biosciences, Joule Unlimited, and Axcella. Since 2008, he has served on the Boston Symphony Orchestra’s Board of Overseers. He is also on the board of the MIT Corporation.

What is Noubar Afeyan's net worth?: The estimated net worth of Noubar Afeyan is at least $87.60 million as of July 31st, 2024. Dr. Afeyan owns 2,224,015 shares of Moderna stock worth more than $87,603,951 as of December 21st. This net worth evaluation does not reflect any other investments that Dr. Afeyan may own. Learn More about Noubar Afeyan's net worth.
How do I contact Noubar Afeyan?: The corporate mailing address for Dr. Afeyan and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected]. Learn More on Noubar Afeyan's contact information.
Has Noubar Afeyan been buying or selling shares of Moderna?: Noubar Afeyan has not been actively trading shares of Moderna during the last quarter. Most recently, Noubar Afeyan sold 15,000 shares of the business's stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $119.96, for a transaction totalling $1,799,400.00. Following the completion of the sale, the director now directly owns 2,224,015 shares of the company's stock, valued at $266,792,839.40. Learn More on Noubar Afeyan's trading history.
Who are Moderna's active insiders?: Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (Chief Executive Officer), W. Cornwell (Director), Arpa Garay (Insider), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Jamey Mock (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.
Are insiders buying or selling shares of Moderna?: During the last year, insiders at the sold shares 49 times. They sold a total of 647,813 shares worth more than $81,384,380.50. The most recent insider tranaction occured on December, 9th when insider Shannon Thyme Klinger sold 529 shares worth more than $23,635.72. Insiders at Moderna own 15.7% of the company. Learn More about insider trades at Moderna.
Information on this page was last updated on 12/9/2024.

Noubar Afeyan Insider Trading History at Moderna

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/31/2024	Sell	15,000	$119.96	$1,799,400.00	2,224,015
7/24/2024	Sell	15,000	$117.80	$1,767,000.00	2,239,015
7/17/2024	Sell	15,000	$122.84	$1,842,600.00	2,254,015
7/10/2024	Sell	15,000	$117.08	$1,756,200.00	2,269,015
6/26/2024	Sell	15,000	$127.22	$1,908,300.00	2,284,015
6/11/2024	Sell	202,832	$148.34	$30,088,098.88	1,528,557
6/5/2024	Sell	15,000	$151.25	$2,268,750.00	1,946,931
5/29/2024	Sell	20,000	$145.08	$2,901,600.00	1,961,931
5/22/2024	Sell	15,000	$157.57	$2,363,550.00	1,981,931
5/15/2024	Sell	15,000	$127.32	$1,909,800.00	1,996,931
5/8/2024	Sell	15,000	$121.68	$1,825,200.00	2,011,931
5/1/2024	Sell	15,000	$110.92	$1,663,800.00	2,026,931
4/24/2024	Sell	15,000	$108.32	$1,624,800.00	2,041,931
4/17/2024	Sell	15,000	$103.38	$1,550,700.00	2,056,931
4/10/2024	Sell	15,000	$107.12	$1,606,800.00	2,071,931
4/3/2024	Sell	15,000	$101.68	$1,525,200.00	2,086,931
3/27/2024	Sell	15,000	$109.06	$1,635,900.00	2,101,931
3/20/2024	Sell	15,000	$102.39	$1,535,850.00	2,116,931
3/13/2024	Sell	15,000	$108.54	$1,628,100.00	2,131,931
11/1/2023	Sell	10,000	$76.00	$760,000.00	2,146,931
10/25/2023	Sell	10,000	$76.99	$769,900.00	2,156,931
10/11/2023	Sell	15,000	$103.30	$1,549,500.00	2,166,931
10/4/2023	Sell	15,000	$102.72	$1,540,800.00	2,181,931
9/27/2023	Sell	10,000	$98.96	$989,600.00	2,196,931
9/20/2023	Sell	15,000	$104.74	$1,571,100.00	2,206,931
9/13/2023	Sell	15,000	$109.70	$1,645,500.00	2,221,931
9/6/2023	Sell	15,000	$107.61	$1,614,150.00	1,982,209
8/30/2023	Sell	15,000	$115.46	$1,731,900.00	1,997,209
8/23/2023	Sell	15,000	$115.51	$1,732,650.00	2,012,209
8/16/2023	Sell	10,000	$97.56	$975,600.00	2,027,209
8/2/2023	Sell	15,000	$110.99	$1,664,850.00	2,037,209
7/26/2023	Sell	15,000	$120.42	$1,806,300.00	2,052,209
7/19/2023	Sell	15,000	$125.48	$1,882,200.00	2,067,209
7/12/2023	Sell	15,000	$125.81	$1,887,150.00	2,082,209
7/5/2023	Sell	15,000	$124.73	$1,870,950.00	2,097,209
6/28/2023	Sell	15,000	$121.54	$1,823,100.00	2,112,209
6/21/2023	Sell	15,000	$121.95	$1,829,250.00	2,127,209
6/7/2023	Sell	15,000	$125.91	$1,888,650.00	2,157,209
5/31/2023	Sell	15,000	$127.35	$1,910,250.00	2,172,209
3/1/2023	Sell	10,000	$139.00	$1,390,000.00	2,187,209
2/22/2023	Sell	10,000	$160.35	$1,603,500.00	2,197,209
2/15/2023	Sell	10,000	$173.17	$1,731,700.00	2,207,209
2/8/2023	Sell	20,000	$167.84	$3,356,800.00	2,217,209
1/25/2023	Sell	10,000	$194.33	$1,943,300.00	2,237,209
1/18/2023	Sell	10,000	$200.20	$2,002,000.00	2,247,209
1/11/2023	Sell	10,000	$188.57	$1,885,700.00	2,257,209
1/4/2023	Sell	10,000	$182.15	$1,821,500.00	2,267,209
12/21/2022	Sell	10,000	$201.70	$2,017,000.00	2,277,209
12/14/2022	Sell	10,000	$195.00	$1,950,000.00	2,287,209
12/7/2022	Sell	10,000	$172.16	$1,721,600.00	2,297,209
11/30/2022	Sell	10,000	$173.52	$1,735,200.00	2,307,209
11/23/2022	Sell	10,000	$178.01	$1,780,100.00	2,317,209
11/16/2022	Sell	10,000	$184.25	$1,842,500.00	2,327,209
11/9/2022	Sell	10,000	$162.50	$1,625,000.00	2,337,209
11/2/2022	Sell	10,000	$154.20	$1,542,000.00	2,347,209
10/26/2022	Sell	10,000	$137.25	$1,372,500.00	2,357,209
10/19/2022	Sell	10,000	$132.50	$1,325,000.00	2,367,209
10/12/2022	Sell	10,000	$135.36	$1,353,600.00	2,377,209
10/5/2022	Sell	10,000	$122.40	$1,224,000.00	2,387,209
9/28/2022	Sell	10,000	$123.58	$1,235,800.00	2,397,209
9/21/2022	Sell	10,000	$130.37	$1,303,700.00	2,407,209
9/14/2022	Sell	10,000	$134.00	$1,340,000.00	2,417,209
9/7/2022	Sell	10,000	$129.68	$1,296,800.00	2,427,209
8/17/2022	Sell	10,000	$165.24	$1,652,400.00	2,447,209
8/10/2022	Sell	10,000	$174.09	$1,740,900.00	2,457,209
8/3/2022	Sell	10,000	$167.99	$1,679,900.00	2,467,209
7/27/2022	Sell	10,000	$161.00	$1,610,000.00	2,477,209
7/20/2022	Sell	10,000	$167.00	$1,670,000.00	2,487,209
7/13/2022	Sell	10,000	$168.88	$1,688,800.00	2,497,209
7/6/2022	Sell	10,000	$154.85	$1,548,500.00	2,507,209
6/29/2022	Sell	10,000	$140.47	$1,404,700.00	2,517,209
6/22/2022	Sell	10,000	$127.69	$1,276,900.00	2,527,209
6/8/2022	Sell	10,000	$147.47	$1,474,700.00	2,537,209
6/1/2022	Sell	10,000	$146.31	$1,463,100.00	2,547,209
5/25/2022	Sell	10,000	$130.80	$1,308,000.00	2,557,209
5/13/2022	Sell	100,000	$134.47	$13,447,000.00	5,816,657
5/11/2022	Sell	10,000	$130.74	$1,307,400.00	2,229,673
3/31/2021	Sell	4,888	$121.07	$591,790.16	2,101,703
3/29/2021	Sell	1,635,122	$124.60	$203,736,201.20	2,101,703
2/24/2021	Sell	1,753,697	$146.19	$256,372,964.43	2,101,703
2/22/2021	Sell	1,836,766	$164.22	$301,633,712.52	2,101,703

Noubar Afeyan Buying and Selling Activity at Moderna

Moderna Company Overview

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $39.39

$39.12

$40.83

50 Day Range

MA: $46.43

$36.85

$57.73

2 Week Range

Now: $39.39

$35.80

$170.47

Volume

35,464,590 shs

Average Volume

5,143,892 shs

Market Capitalization

$15.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now